The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.

ABSTRACT: OBJECTIVE:To evaluate the cost-effectiveness of financial incentives for human immunodeficiency virus (HIV) viral suppression compared to standard of care. STUDY DESIGN:Mathematical model of 2-year intervention offering financial incentives ($70 quarterly) for viral suppression (<400 copies/ml3) based on the HPTN 065 clinical trial with HIV patients in the Bronx, NY and Washington, D.C. METHODS:A disease progression model with HIV transmission risk equations was developed following guidelines from the Second Panel on Cost-Effectiveness in Health and Medicine. We used health care sector and societal perspectives, 3% discount rate, and lifetime horizon. Data sources included trial data (baseline N = 16,208 patients), CDC HIV Surveillance data, and published literature. Outcomes were costs (2

SUBMITTER: Adamson B 

PROVIDER: S-EPMC6362462 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature